Whether coinhibition of one pathway or even the same protein (e.g., DNA topoisomerase IIα) will contribute to supra‐additive efficacy remains unclear,69 but DOX and HDAC inhibitors showed supra‐additive effects in osteosarcoma. The gene discussed is HDAC9; the disease is osteosarcoma.